Oils having antibacterial activity
Inventors
Bischoff, Kenneth M. • Leathers, Timothy D. • Price, Neil P. • MANITCHOTPISIT, Pennapa
Assignees
US Department of Agriculture USDA
Publication Number
US-9950986-B2
Publication Date
2018-04-24
Expiration Date
2035-03-16
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Novel compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed. where R1 is either COCH3 or H; and R2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R3 is D-mannitol, R2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.
Core Innovation
This invention discloses novel compounds called liamocins produced by Aureobasidium pullulans, having the general chemical structure in Formula 1. The formula includes variables R1 as either COCH3 or H; R2 as between two to ten O-linked 3,5-dihydroxydecanoate; and R3 as a polyol selected from a specified group including glycerol, threitol, erythritol, arabitol, xylitol, mannitol, and others. When R3 is D-mannitol, certain constraints on R2 apply. These liamocins, either individually or in combination, possess antibacterial activity, capable of killing certain bacteria and treating bacterial infections.
The problem addressed arises from the limited effectiveness and undesirable aspects of antibiotics traditionally used to prevent or treat infections caused by Streptococcus spp. and related bacteria. In dairy cattle, mastitis caused by such bacteria necessitates systemic antibiotic administration that risks milk contamination and antibiotic resistance development. There is a need for new methods and compositions effectively killing or inhibiting growth of these bacteria with improved safety profiles.
The invention provides isolated and purified liamocins and compositions containing them for use as topical disinfectants, transdermal or systemic antibacterial agents, applicable to animals including mammals, birds, fish, amphibians, and reptiles. Methods of production are also disclosed, enabling generation of liamocins with specific head groups by culturing Aureobasidium pullulans on media containing target polyols. The antibacterial uses extend to killing or preventing growth of Streptococcus spp., Enterococcus spp., and Bacillus spp. on animals or surfaces.
Claims Coverage
The patent contains four independent claims covering compositions and methods of use of liamocins with antibacterial activity.
Composition comprising liamocins for antibacterial activity
A composition containing one or more compounds of Formula 1, optionally with a carrier and diluent, wherein the compounds kill Streptococcus spp., Enterococcus spp., and Bacillus spp.
Method of treating bacterial diseases in animals using liamocin composition
A method to treat diseases caused by Streptococcus spp., Enterococcus spp., or Bacillus spp. in animals by administering a therapeutically effective amount of a composition containing an oil of chemical structure Formula 1 to kill the bacteria.
Use of specific liamocin variants in treatment methods
The oil in the treatment method comprises specific liamocins selected from a defined group including L- and D- isomers of mannitol, arabitol, threitol, glycerol liamocin variants A1, A2, B1, and B2.
Methods for reducing or killing bacterial populations on surfaces with liamocin compositions
Methods involving application of an effective amount of a composition containing an oil of Formula 1 to reduce or kill populations of Streptococcus spp., Enterococcus spp., or Bacillus spp. on surfaces, optionally comprising the specified liamocin variants.
The independent claims collectively cover the compositions of liamocins and their use in treating bacterial diseases in animals and controlling bacterial populations on surfaces, highlighting the chemical structure of the compounds and the specific liamocin variants effective against targeted bacteria.
Stated Advantages
The liamocins and compositions containing liamocins exhibit bactericidal activity against agriculturally and medically important bacteria such as Streptococcus spp., Enterococcus spp., and Bacillus spp.
The antibacterial activity remains stable after heat treatment such as autoclaving, suggesting durability and robustness of the compounds.
The liamocins can be applied via multiple routes including topical, oral, rectal, or parenteral administration, providing versatile treatment options.
They can be used for therapeutic, preventive, and disinfectant purposes on animals and surfaces, offering broad potential utility.
Methods to produce liamocins with specific polyol head groups allow tailored production of antibacterial compounds.
Documented Applications
Treatment of bacterial infections caused by Streptococcus spp., Enterococcus spp., and Bacillus spp. in animals, including mammals, birds, fish, amphibians, and reptiles.
Use as a topical disinfectant or transdermal antibacterial agent to kill or inhibit bacteria on the skin or surfaces of animals.
Use as systemically administered antibacterial agents for treating diseases in animals caused by susceptible bacteria.
Application as disinfectants on surfaces such as counters, walls, floors, medical and veterinary instruments, and various foods.
Use as teat dips to reduce Streptococcus agalactiae associated with bovine mastitis.
Use in mouthwash formulations to reduce oral bacteria such as Streptococcus mutans in humans.
Interested in licensing this patent?